09:23 AM EDT, 05/31/2024 (MT Newswires) -- Novartis ( NVS ) said Friday that the late-stage trial for its treatment for chronic myeloid leukemia, Scemblix, has met both of its primary endpoints.

Scemblix demonstrated clinically significant efficacy that was better than select standard-of-care therapies of the same type, the drugmaker said.

The drug's safety profile was consistent with previous studies with no new safety concerns observed, Novartis ( NVS ) said.

Price: 102.29, Change: +1.59, Percent Change: +1.58